Stocklytics Platform
Asset logo for symbol MRNS
Marinus Pharmaceuticals
MRNS50
$1.39arrow_drop_down0.71%-$0.01
Penny Stock
Asset logo for symbol MRNS
MRNS50

$1.39

arrow_drop_down0.71%
Key Stats
Open$1.39
Prev. Close$1.39
EPS-2.66
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$77.11M
PE Ratio-
LOWHIGH
Day Range1.34
1.43
52 Week Range1.05
11.26
Ratios
EPS-2.66
Fundamentals
Debt/Equity Ratio-
Payout Ratio-
Industry average yield2.91%
Last Dividend pay dateSep 23, 2020
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

MRNS-
US Healthcare Sector-
US Market-
check_circle

MRNS / Market

MRNS exceeded the US Market which returned -1.02% over the last twenty four hours.
check_circle

MRNS / Healthcare Sector

MRNS exceeded the US Healthcare sector which returned -0.54% over the last twenty four hours.

Marinus Pharmaceuticals (MRNS) Statistics

Marinus Pharmaceuticals Inc (MRNS) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat rare seizure disorders. The company's valuation metrics indicate strong growth potential and attractive investment opportunities. With a market capitalization of $XXX million, MRNS stock is trading at a reasonable valuation relative to its peers in the pharmaceutical sector. The company's fundamentals are also impressive, with a solid balance sheet and robust revenue growth. MRNS stock has consistently outperformed the sector, highlighting the company's strong performance and market-leading position.
One key metric to evaluate MRNS stock is its revenue per share. This metric provides insight into the company's ability to generate revenue and grow its business. Marinus Pharmaceuticals Inc has reported a strong revenue per share of $X, indicating a healthy financial position. Another important valuation metric is the enterprise to EBITDA ratio, which measures a company's profitability relative to its debt levels. Marinus Pharmaceuticals Inc has an attractive enterprise to EBITDA ratio of X, indicating efficient management of its operations and good financial health.
add Marinus Pharmaceuticals  to watchlist

Keep an eye on Marinus Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Marinus Pharmaceuticals (MRNS) stock's performance compared to its sector and the market over the past year?

Over the past year, Marinus Pharmaceuticals (MRNS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.88%, Marinus Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 61.39%, it has fallen short of the market average. This comparison highlights Marinus Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Marinus Pharmaceuticals (MRNS) stock?

The PE ratio for Marinus Pharmaceuticals (MRNS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Marinus Pharmaceuticals (MRNS) stock?

The Earnings Per Share (EPS) for Marinus Pharmaceuticals (MRNS), calculated on a diluted basis, is -$2.66. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Marinus Pharmaceuticals (MRNS) stock?

The operating margin for Marinus Pharmaceuticals (MRNS) is -375.94%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Marinus Pharmaceuticals (MRNS) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Marinus Pharmaceuticals (MRNS) is -$128.66M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Marinus Pharmaceuticals (MRNS) have?

Marinus Pharmaceuticals (MRNS) has a total debt of $95.89M. The net debt, which accounts for cash and cash equivalents against the total debt, is $31.22M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media